PTC Therapeutics' Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial; OMS721 Inhibits Thrombus Formation Print E-mail
By Marilyn Mullen   
Wednesday, 19 November 2014 20:00
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 19, 2014.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a Phase 1b/2a study in adult and pediatric patients. The placebo-controlled, randomized, multiple-dose study will enroll approximately 48 patients with SMA and investigate the safety and tolerability of an investigational survival of motor neuron 2 (SMN2) gene splicing modifier (RG7800) over 12 weeks. The achievement of this milestone triggers a $10 million payment to PTC from Roche.

"We are excited to initiate the next phase of this program and begin a trial in SMA patients with our partners," stated Stuart Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. "We believe that the encouraging clinical results and preclinical data from relevant disease models are promising indications that the orally administered small molecule RG7800 has the potential to modify the splicing of the SMN2 gene and generate more full-length SMN mRNA in SMA patients. The advancement of this potential new treatment, which could represent the first orally available SMN2 splicing modifier for SMA, is a significant milestone for patients and their families."

As previously reported, the Phase 1 single-ascending dose study in healthy volunteers demonstrated that all doses studied were safe, well tolerated and demonstrated a dose-dependent effect on SMN2 splicing as shown by a change in the ratio of full-length SMN2 mRNA to SMN2 mRNA without exon 7 (SMND7), which is interpreted as proof of mechanism in terms of the expected pharmacodynamic effect.

SMA is caused by a missing or defective SMN1 gene, which results in reduced levels of SMN protein. This genetic neuromuscular disease is responsible for the loss of motor neurons within the spinal cord leading to muscle atrophy and death at infant age in its most severe form. We believe the oral small molecule RG7800 may have the potential to target the underlying cause of the disorder by increasing SMN protein levels in the nervous system, muscles, and other tissues. It is estimated that one in 10,000 children in the United States are born with this rare disorder.

The SMA program was initially developed by PTC Therapeutics in partnership with the SMA Foundation. The SMA Foundation was established in 2003 to accelerate the development of a treatment for SMA. In November 2011, Roche gained an exclusive worldwide license to the PTC/ SMAF SMA program. The development of RG7800 is being led by Roche and overseen by a joint steering committee with members from Roche, PTC and the SMA Foundation.



 
=====================================

 

 
Omeros Corporation (NASDAQ: OMER)
announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, to inhibit thrombus formation in an ex vivo pathophysiologic system of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. OMS721 is currently in a Phase 2 clinical program evaluating the drug's efficacy in treating TMAs, including aHUS.

The data announced today resulted from studies in a well-established experimental model of TMA aimed at assessing the potential therapeutic benefits of OMS721 in TMA using serum samples from aHUS patients with different etiologies obtained during the acute phase of disease as well as during remission. The studies were conducted by Prof. Giuseppe Remuzzi and colleagues Marina Noris and Miriam Galbusera at the Mario Negri Institute for Pharmacological Research in Bergamo, Italy, and the Clinical Research Center for Rare Diseases "Aldo e Cele Dacco" of the same institute, a European center for the study of TMA. The experimental model is based on the finding that sera from aHUS patients promote the formation of thrombi on human microvascular endothelial cells, the defining pathological feature of TMA.

The studies reported today showed that OMS721 significantly inhibited thrombus formation when added to serum samples from aHUS patients obtained during the acute phase of disease (p<0.01) as well as during remission (p<0.0001). OMS721 was as effective at inhibiting thrombus formation as the positive control in the studies – soluble complement receptor 1, an agent that completely blocks the complement system.

Earlier this year, Omeros reported that OMS721 also significantly inhibited complement deposition compared to control treatment in an experimental ex vivo pathophysiologic system of complement activation in TMA, again using serum samples from aHUS patients obtained during the acute phase of disease (p<0.01) and during remission (p<0.001). Prof. Remuzzi's laboratories have previously shown in the same complement-activation model that eculizumab (Soliris®), a monoclonal antibody blocking the complement factor C5 that is approved by the FDA and the European Medicines Agency to treat patients with aHUS, also inhibited complement deposition. Data recently published indicate that the ex vivo pathophysiologic system established by Prof. Remuzzi and his colleagues may be useful in assessing the clinical effectiveness of anti-complement therapy in aHUS (Noris et al., Blood (2014) 124:1715).

"We believe that the notable anti-complement and anti-thrombotic activities of OMS721 in serum samples from aHUS patients bode well for the therapeutic potential of OMS721 in thrombotic microangiopathies," stated Prof. Remuzzi, MD, FRCP, Research Coordinator at the Mario Negri Institute and international expert in the study of kidney disease who has contributed major advances to the understanding of the pathophysiology of hemolytic uremic syndrome.

Having demonstrated that the lectin pathway, and MASP-2 specifically, are involved in the pathophysiology of aHUS, Prof. Remuzzi and his team are currently conducting additional experiments to understand the mechanism by which OMS721 blocks ex vivo thrombus formation in aHUS and its effect on endothelial cells, platelets and the alternative pathway of complement.

"Thrombus formation is the central pathological feature of aHUS and other TMAs, so we are particularly pleased with the robust anti-thrombotic activity in serum samples from aHUS patients," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "We believe that these most recent data from Prof. Remuzzi's laboratories meaningfully de-risk our '721 Phase 2 program in TMAs, including aHUS, and we look forward to reporting preliminary efficacy and safety data from the ongoing clinical trial."


 
Also Wednesday:



Bio Blast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today that it has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for Cabaletta for the treatment of Spinocerebellar Ataxia Type 3 (commonly known as SCA3 and Machado Joseph disease).

BioTelemetry, Inc. (Nasdaq:BEAT),
the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that after 13 years of distinguished service, Eric Prystowsky M.D., will transition from his position as a Director and enter into a multi-year agreement to serve as a Medical Advisor for the Company.

CombiMatrix Corporation (Nasdaq:CBMX)
, a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the promotions of Karine Hovanes, Ph.D., to Vice President of Scientific Advancement and Laboratory Director and Trilochan Sahoo, M.D., to Vice President of Clinical Affairs and Director of Cytogenetics.

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today presented new data that showed Vectra® DA is a better predictor of radiographic progression over two years than other tests used to assess risk of joint damage in rheumatoid arthritis (RA), such as C-reactive protein (CRP). The oral presentation was featured at the 2014 American College of Rheumatology (ACR) Annual Meeting in Boston, Massachusetts.

Cellular Biomedicine Group Inc. (Nasdaq:CBMG)
, a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today reported financial results and provided business highlights for the third quarter ended September 30, 2014.

Foundation Healthcare (OTCQB:FDNH)
, which owns and operates surgically focused hospitals and related ancillary services, announced today that Mr. Stanton Nelson, CEO, will make a presentation at the LD Micro conference, which will be held at the Luxe Sunset Bel Air on Tuesday, December 2, 2014.

iKang Healthcare Group, Inc. (Nasdaq:KANG)
, the largest provider in China's fast growing private preventive healthcare services market in terms of revenue in 2013, today announced the acquisition of three medical centers in Shenyang that are franchised from Ciming Checkup Group.

Johns Hopkins Medicine (JHM) and Premier, Inc. (Nasdaq:PINC) have agreed to collaborate on the development of innovative clinical and operational models designed to improve healthcare quality, safety and value, as well as impact overall wellness.

K2M Group Holdings, Inc. (Nasdaq:KTWO), a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine and minimally invasive spine technologies and techniques, today announced that management will participate in the Piper Jaffray 26th Annual Healthcare Conference at The New York Palace on Dec. 3, 2014.

Medical Marijuana Inc. (OTC Pink:MJNA), a leading cannabis and industrial hemp industry innovator, today announced the release of its quarterly financial and shareholders report (Post 11/13/2014 - OTC Markets).

MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that its Board of Directors has named Michael R. Stewart, 57, as the company's next President and Chief Executive Officer, effective December 15.

Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of Nuvilex's pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals.

Oxford Performance Materials Inc. (OPM) today announced that it has received a three-year, $150,000 grant from the National Institutes of Health (NIH) to explore new approaches to improve the treatment of infections related to artificial hips, knees and other implanted devices through advanced applications of 3D printed poly-ether-ketone-ketone (PEKK).

PositiveID Corporation (OTCQB:PSID), a developer of biological detection and diagnostics solutions, announced today its highlights for the third quarter ended September 30, 2014, and also filed its Form 10-Q, which can be found at: http://investors.positiveidcorp.com/secfiling.cfm?filingID=1144204-14-69180&CIK=1347022.

Sanomedics International Holdings, Inc. (OTCQB:SIMH), a medical technology holding company that focuses on providing game changing products, services and ideas, announced today its financial results for the third quarter 2014.

Tornier N.V. (Nasdaq:TRNX), a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, announced today that David Mowry, the Company's President and Chief Executive Officer, and Shawn McCormick, the Company's Chief Financial Officer, will present at the Piper Jaffray 26th Annual Healthcare Conference.

ZS Pharma (Nasdaq:ZSPH)
, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that it has made available on its website the presentation from the Company's R&D Review and Key Opinion Leader Panel, which took place on Wednesday, November 19, 2014 in New York.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter